However, the low target engagement and dose-limiting thrombocytopenia limits the use of Bcl-xL inhibitors (e.g. ABT263 and A-1155463) as safe and effective anticancer agents [205]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.